This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

InOncology.com

Treatment Sequence | NSCLC | InOncology

BI understand that continuing clinical research is needed to give better patient outcomes.  Please see below to discover more about TKI sequencing and the video we have developed to illustrate the ever evolving landscape for treatment of EGFRM+ NSCLC.

Activating mutations in the epidermal growth factor receptor (EGFR) are known to be a driver of non-small cell lung carcinoma (NSCLC), and tyrosine kinase inhibitors (TKIs) that target these mutations are currently standard of care for first-line therapy in patients with EGFR mutation positive (EGFRM+) NSCLC. However, patients with EGFRM+ disease eventually develop acquired resistance to these therapies, which most commonly occurs via T790M mutations1. The clinical development of 3rd generation TKIs provides additional treatment options for these patients and can extend the chemotherapy-free interval. For clinicians seeking to further improve patient outcomes, this progress in clinical development raises questions about the optimal sequence of EGFR TKI therapies. Additional data are required to further inform this important clinical topic.  

 

Afatinib* is an irreversible ErbB Family blocker that selectively, potently and irreversibly binds to and blocks EGFR2,3.  The video below shows how the landscape for treatment for EGFRM+ NSCLC has evolved, and how insights from afatinib* clinical trials can inform treatment sequencing for patients with EGFRM+ NSCLC.

 

To find out more about available clinical data on afatinib and treatment sequencing, please visit the afatinib clinical trial data and the NSCLC additional analyses and further trials pages.

 

Sequencing: The Bigger Picture

3 min 34 sec
Rate this

References

1

 Novello S, et al. Ann Oncol 2016;27(suppl 5):v1–27.

2

Reid A, et al. Eur J Cancer 2007;43(3):481-9.

3

Li D, et al. Oncogene 2008;27(34):4702-11.

*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.